17th Apr 2024 11:30
17 April 2024
ReNeuron Group plc
("ReNeuron", the "Group" or the "Company")
Resignation of Chief Financial Officer
ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that John Hawkins will be stepping down as Chief Financial Officer ("CFO") of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.
Iain Ross, Executive Chairman, said:
"The Board takes this opportunity to thank John for his valued contribution to the Group during his tenure and wish him every success for the future."
Enquiries:
Cork Gully LLP | +44 (0)20 7268 2150 or | ||
Stephen Cork, Joint Administrator | |||
Mark Smith, Joint Administrator | |||
| |||
ReNeuron | www.reneuron.com/investors | ||
Iain Ross, Executive Chairman | Via Walbrook PR | ||
Allenby Capital Limited (Nominated Adviser and Broker) | +44 (0)20 3328 5656 | ||
James Reeve/George Payne/ Dan Dearden-Williams (Corporate Finance) | |||
Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking) | |||
Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or [email protected] | ||
Paul McManus / Alice Woodings | +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
Related Shares:
RENE.L